Silent nucleotide substitution in the sterol 27-hydroxylase gene (CYP 27) leads to alternative pre-mRNA splicing by activating a cryptic 5′ splice site at the mutant codon in cerebrotendinous xanthomatosis patients

被引:36
作者
Chen, W
Kubota, S
Teramoto, T
Nishimura, Y
Yonemoto, K
Seyama, Y
机构
[1] Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, Tokyo 1130033, Japan
[2] Teikyo Univ, Fac Med, Dept Internal Med 1, Itabashi Ku, Tokyo 1730003, Japan
[3] Jikei Med Sch, Dept Rehabil, Tokyo 2010003, Japan
关键词
D O I
10.1021/bi972940a
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A functionally silent nucleotide substitution of the sterol 27-hydroxylase gene (CYP 27), identified in two families with cerebrotendinous xanthomatosis (CTX), was confirmed to cause alternative pre-mRNA splicing of the gene. Full-length RT-PCR analysis of the CYP 27 gene in a patient from one of the CTX families revealed one major and an additional faint band. Sequence analysis of the cloned RT-PCR product showed three species of cDNA: 3' terminal 13 bp of exon 2 deleted cDNA, exon 2 skipped cDNA, and full-length cDNA with a functionally silent G to T mutation at codon 112 (GGG (112)Gly to GGT (112)Gly). Only a single base change was identified by genomic DNA sequence analysis of the CYP 27 gene in the patient: T replaced G at the third position of codon 112, 13 bp upstream from the 3' terminus of exon 2. Transfection of constructed minigenes, with or without the mutation, confirmed that this silent mutation resulted in alternative pre-mRNA splicing by activating a cryptic 5' splice site around the mutant codon. The mutation was also identified in two patients from another CTX family, with a compound heterozygous pattern of A for G substitution at codon 372, a mutation reported previously by our group. The results elucidate a novel molecular basis for the CTX and suggest the significance of a silent nucleotide substitution with regard to pre-RNA splicing.
引用
收藏
页码:4420 / 4428
页数:9
相关论文
共 35 条
[1]   OSTEOPOROSIS AND INCREASED BONE-FRACTURES IN CEREBROTENDINOUS XANTHOMATOSIS [J].
BERGINER, VM ;
SHANY, S ;
ALKALAY, D ;
BERGINER, J ;
DEKEL, S ;
SALEN, G ;
TINT, GS ;
GAZIT, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (01) :69-74
[2]   LONG-TERM TREATMENT OF CEREBROTENDINOUS XANTHOMATOSIS WITH CHENODEOXYCHOLIC ACID [J].
BERGINER, VM ;
SALEN, G ;
SHEFER, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (26) :1649-1652
[3]   OMEGA-HYDROXYLATION OF STEROID SIDE-CHAIN IN BIOSYNTHESIS OF BILE-ACIDS [J].
BJORKHEM, I ;
GUSTAFSSON, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1973, 36 (01) :201-212
[4]  
CALI JJ, 1991, J BIOL CHEM, V266, P7774
[5]  
CALI JJ, 1991, J BIOL CHEM, V266, P7779
[6]   QUANTITATIVE ESTIMATION OF MINOR MESSENGER-RNAS BY CDNA-POLYMERASE CHAIN-REACTION - APPLICATION TO DYSTROPHIN MESSENGER-RNA IN CULTURED MYOGENIC AND BRAIN-CELLS [J].
CHELLY, J ;
MONTARRAS, D ;
PINSET, C ;
BERWALDNETTER, Y ;
KAPLAN, JC ;
KAHN, A .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 187 (03) :691-698
[7]  
Chen W, 1997, J LIPID RES, V38, P870
[8]  
CHEN W, 1998, IN PRESS J LIPID RES
[9]   Genetic analysis of a Japanese cerebrotendinous xanthomatosis family: Identification of a novel mutation in the adrenodoxin binding region of the CYP 27 gene [J].
Chen, WG ;
Kubota, S ;
Nishimura, Y ;
Nozaki, S ;
Yamashita, S ;
Nakagawa, T ;
KamedaTakemura, K ;
Menju, M ;
Matsuzawa, Y ;
Bjorkhem, I ;
Eggertsen, G ;
Seyama, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1996, 1317 (02) :119-126
[10]   ATHEROGENIC RISK-FACTORS IN CEREBROTENDINOUS XANTHOMATOSIS [J].
FUJIYAMA, J ;
KURIYAMA, M ;
ARIMA, S ;
SHIBATA, Y ;
NAGATA, K ;
TAKENAGA, S ;
TANAKA, H ;
OSAME, M .
CLINICA CHIMICA ACTA, 1991, 200 (01) :1-11